The cardiac benefit of androgen replacement in hypogonadal males with coronary artery disease following successful percutaneous coronary intervention (PCI).

Trial Profile

The cardiac benefit of androgen replacement in hypogonadal males with coronary artery disease following successful percutaneous coronary intervention (PCI).

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2015

At a glance

  • Drugs Testosterone (Primary)
  • Indications Coronary artery disease; Hypogonadism
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 10 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov
    • 10 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top